-
Association of hypophosphatemia during continuous kidney replacement therapy and clinical outcomes: a systematic review and meta-analysis. Blood Purif. (IF 2.2) Pub Date : 2024-09-12 Lu Jin,Peiyun Li,Qing Xv,Linshen Xie,Ling Zhang
INTRODUCTION Hypophosphatemia is a common and potentially severe complication of continuous kidney replacement therapy (CKRT), but the evidence on the correlation between hypophosphatemia occurring during CKRT and clinical outcomes remains limited. METHODS Electronic databases (PubMed, Embase, Web of Science, and the Cochrane database) were searched from inception to March 1, 2024. All possible studies
-
Is endovascular arteriovenous fistula a feasible alternative for hemodialysis patients? Blood Purif. (IF 2.2) Pub Date : 2024-09-12 Hugo Vergara-Pérez,Raúl Diaitz-Usetxi Laplaza,Alejandro Pérez Alba,Pablo Baliño Remiro,Asunción Rius Peris,M Ángeles Fenollosa Segarra,Alejandro Tamayo Vasquez,Javier Reque
INTRODUCTION For hemodialysis (HD) patients, the selection of vascular access (VA) is a crucial factor that significantly affects morbidity and mortality. Historically, native Arteriovenous Fistulas (AVFs) have been established using surgical techniques. However, devices facilitating percutaneous endovascular arteriovenous fistula formation have recently been introduced in clinical practice, showing
-
Effect of dialysis on structural brain connectivity in patients with end-stage renal disease. Blood Purif. (IF 2.2) Pub Date : 2024-09-05 Byeongo Choi,Chang Min Heo,Jiyae Yi,Dong Ah Lee,Yoo Jin Lee,Sihyung Park,Yang Wook Kim,Junghae Ko,Bong Soo Park,Kang Min Park
INTRODUCTION Patients with end-stage renal disease (ESRD) are known to have reduced structural and functional brain connectivity in the brain regions associated with cognitive function. However, the effect of dialysis on brain connectivity remains unclear. This study aimed to evaluate the effects of dialysis on structural brain connectivity in patients with ESRD. METHODS This prospective study included
-
Effect of change in sodium after slow low-efficiency dialysis (SLED) in critically ill patients with acute kidney injury. Blood Purif. (IF 2.2) Pub Date : 2024-09-05 Sai Saran,Namrata S Rao,Saumitra Misra,Suhail Sarwar Siddiqui,Avinash Agrawal,Ayush Lohiya,Mohan Gurjar,Prabhaker Mishra,Syed Nabeel Muzaffar
INTRODUCTION The effect of change in sodium (Na) in critically ill patients undergoing slow low-efficiency dialysis (SLED) is unclear. METHODS Prospective observational study enrolled dysnatremic critically ill adult patients with acute kidney injury (AKI) undergoing the first SLED as cases and normonatremic patients as controls. Baseline and SLED-related parameters, and 30-day mortality were noted
-
A Pilot and Feasibility Study of Continuous Cardiac Output and Blood Pressure Monitoring during Intermittent Hemodialysis. Blood Purif. (IF 2.2) Pub Date : 2024-09-02 Sofia Spano,Akinori Maeda,Joey Lam,Anis Chaba,Atthaphong Phongphithakchai,Nuttapol Pattamin,Yukiko Hikasa,Emily See,Peter Mount,Rinaldo Bellomo
INTRODUCTION Hypotension is common during intermittent hemodialysis (IHD) and may be due to a decreased cardiac index (CI). However, no study has simultaneously and continuously measured CI and mean arterial pressure (MAP) to understand the prevalence, severity, and duration of CI decreases or relate them to MAP, blood volume (BV) and net ultrafiltration (NUF) rate. METHODS In a prospective, pilot
-
Peripheral Blood Lymphocyte Subgroups in Patients Undergoing Hemodialysis with Medium Cut-Off Membranes and High-Flux Membranes: THE SHE Continuation Study. Blood Purif. (IF 2.2) Pub Date : 2024-08-30 Nuri Baris Hasbal,Mustafa Sevinc,Vuslat Yilmaz,Abdullah Yılmaz,Hande Yuceer Korkmaz,Taner Basturk,Elbis Ahbap,Tamer Sakaci,Bengt Lindholm,Abdulkadir Unsal
INTRODUCTION Chronic kidney disease (CKD) poses a significant global health burden, with increasing prevalence and high morbidity and mortality rates, particularly in end-stage kidney disease (ESKD). While traditional risk factors contribute, the exact mechanisms remain elusive, with inflammation playing a pivotal role. Medium cut-off (MCO) membranes offer promise in improving dialysis outcomes by
-
Generative AI in Critical Care Nephrology: Applications and Future Prospects. Blood Purif. (IF 2.2) Pub Date : 2024-08-30 Wisit Cheungpasitporn,Charat Thongprayoon,Claudio Ronco,Kianoush B Kashani
BACKGROUND Generative artificial intelligence (AI) is rapidly transforming various aspects of healthcare, including critical care nephrology. Large language models (LLMs), a key technology in generative AI, show promise in enhancing patient care, streamlining workflows, and advancing research in this field. SUMMARY This review analyzes the current applications and future prospects of generative AI
-
CaCl2-citrate regional anticoagulation with CVVHD leads to unwanted chloride loading compared to CVVH with systemic anticoagulation. Blood Purif. (IF 2.2) Pub Date : 2024-08-30 Matthieu Chivot,Ian Baldwin,Guillaume Deniel,Guillaume David,Glenn M Eastwood,Jean-Christophe Richard,Rinaldo Bellomo,Laurent Bitker
INTRODUCTION Chloride transfers during continuous renal replacement therapy (CRRT) have not been adequately described and may differ based on CRRT technique. We aimed to measure chloride mass transfer (JS,Cl) during CRRT and identify associated determinants. METHODS We performed a two-center, prospective, observational study in France and Australia in ICU patients with CRRT initiated for < 24h. Patients
-
Chemokine (C-C Motif) Ligand 14 to Predict Persistent Severe Acute Kidney Injury: a Systematic Review and Meta-analysis. Blood Purif. (IF 2.2) Pub Date : 2024-08-24 Nicolas Tebib,Céline Monard,Thomas Rimmelé,Antoine Schneider
INTRODUCTION In this systematic review and meta-analysis, we aimed to review available data and provide pooled estimates of the predictive performance of urinary chemokine (CC motif) ligand (uCCL14') for persistent (≥48 hours) severe acute kidney injury (PS-AKI). METHODS We searched MEDLINE, PubMed, Cochrane Library, and EMBASE for studies published up to April 11, 2023. We considered all studies including
-
Selected abstracts from the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology. Blood Purif. (IF 2.2) Pub Date : 2024-08-22
Selected abstracts from the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology.
-
Relative Blood Volume Monitoring during Continuous Renal Replacement Therapy: A Prospective Observational Study. Blood Purif. (IF 2.2) Pub Date : 2024-08-13 Akinori Maeda,Ian Baldwin,Sofia Spano,Anis Chaba,Atthaphong Phongphithakchai,Nuttapol Pattamin,Yukiko Hikasa,Rinaldo Bellomo,Emily See
INTRODUCTION Hematocrit monitoring during continuous renal replacement therapy (CRRT) allows the continuous estimation of relative blood volume (RBV). This may enable early detection of intravascular volume depletion prior to clinical sequelae. We aimed to investigate the feasibility of extended RBV monitoring and its epidemiology during usual CRRT management by clinicians unaware of RBV. Moreover
-
Coagulation Risk Predicting in Anticoagulant-Free Continuous Renal Replacement Therapy. Blood Purif. (IF 2.2) Pub Date : 2024-08-12 Liang Liu,Dashuang Liu,Ting He,Bo Liang,Jinghong Zhao
INTRODUCTION Continuous renal replacement therapy (CRRT) is a prolonged continuous extracorporeal blood purification therapy to replace impaired renal function. Typically, CRRT therapy requires routine anticoagulation, but for patients at risk of bleeding and with contraindications to sodium citrate, anticoagulant-free dialysis therapy is necessary. However, this approach increases the risk of CRRT
-
The Mitochondrial-Derived Peptide MOTS-c May Refine Mortality and Cardiovascular Risk Prediction in Chronic Hemodialysis Patients: A Multicenter Cohort Study. Blood Purif. (IF 2.2) Pub Date : 2024-08-07 Davide Bolignano,Marta Greco,Pierangela Presta,Anila Duni,Mariateresa Zicarelli,Simone Mercuri,Efthymios Pappas,Lampros Lakkas,Michela Musolino,Katerina K Naka,Roberta Misiti,Daniela Patrizia Foti,Michele Andreucci,Giuseppe Coppolino,Evangelia Dounousi
INTRODUCTION Uremic patients exhibit remarkably increased rates of mortality and cardiovascular (CV) events, but risk prediction in this setting remains difficult. Systemic mitochondrial dysfunction is pervasive in end-stage kidney disease and may contribute to CV complications. We tested the clinical significance of circulating MOTS-c, a small mitochondrial-derived peptide, as a biomarker for improving
-
The Role of Early Hemoadsorption in Severe COVID-19 Treatment: A Pilot Randomized Controlled Trial. Blood Purif. (IF 2.2) Pub Date : 2024-08-05 Karjbundid Surasit,Nattachai Srisawat
INTRODUCTION Hemoadsorption, an extracorporeal apheresis technique, is reportedly used in severe COVID-19 patients. However, limited evidence from randomized clinical trials supports this practice. METHODS In this single-center study, severe COVID-19 patients requiring ICU admission were randomly assigned (1:1) to receive HA-330 hemoadsorption in combination with standard treatment or standard therapy
-
Haptoglobin Administration for Intravascular Hemolysis: A Systematic Review. Blood Purif. (IF 2.2) Pub Date : 2024-08-05 Luca Baldetti,Rosa Labanca,Alessandro Belletti,André Dias-Frias,Beatrice Peveri,Yuki Kotani,Stefano Fresilli,Francesco Calvo,Evgeny Fominskiy,Marina Pieri,Silvia Ajello,Anna Mara Scandroglio
INTRODUCTION Exogenous haptoglobin administration may enhance plasma-free hemoglobin (pfHb) clearance during hemolysis and reduce its end-organ damage: we systematically reviewed and summarized available evidence on the use of haptoglobin as a treatment for hemolysis of any cause. METHODS We included studies describing haptoglobin administration as treatment or prevention of hemolysis-related complications
-
Construction of Risk-Prediction Models for Autogenous Arteriovenous Fistula Thrombosis in Patients on Maintenance Hemodialysis. Blood Purif. (IF 2.2) Pub Date : 2024-08-01 Xiaoyu Jin,Yuying Fan,Jingshu Li,Xiaona Qi,Xue Li,Hongyi Li
INTRODUCTION Autogenous arteriovenous fistula (AVF) is the preferred vascular access in patients undergoing maintenance hemodialysis (MHD). However, complications such as thrombosis may occur. This study aimed to construct and validate a machine learning-based risk-prediction model for AVF thrombosis, hypothesizing that such a model can effectively predict occurrences, providing a foundation for early
-
Human Proenkephalin A 119-159 (penKid) in Extracorporeal Therapies: Ex vivo Sieving Coefficient, Diffusive Clearance, and Hemoadsorption Kinetics. Blood Purif. (IF 2.2) Pub Date : 2024-07-26 Anna Lorenzin,Massimo de Cal,Natascha Perin,Niccolò Morisi,Alessandra Brendolan,Paolo Lentini,Monica Zanella,Claudio Ronco
INTRODUCTION Enkephalins, endogenous opioid peptides, are involved in the regulation of renal function. One derived molecule, proenkephalin A, also known as penKid, has been demonstrated to be a reliable biomarker for kidney function and its plasma concentration correlates with measured glomerular filtration rate. penKid is used for prediction and diagnosis of AKI and need of renal replacement therapy
-
Protein-Bound Uremic Toxins and Inflammation Process in Hemodialysis Patients: Is There a Role for Adsorption Hemodiafiltration? Blood Purif. (IF 2.2) Pub Date : 2024-07-24 Paolo Fabbrini,Denise Vergani,Anna Malinverno,Federico Pieruzzi,Marita Marengo,Guido Merlotti,Claudio Medana,Alessandro Domenico Quercia,Vincenzo Cantaluppi
INTRODUCTION Despite major advances in the field of dialysis, there are still some unmet needs such as reducing inflammation through adequate depuration. It is well known that the wide spectrum of pro-inflammatory and pro-atherosclerotic uremic toxins are inefficiently removed by current dialysis techniques. Adsorption seems to be an extra tool to remove toxins, but its effect and optimization have
-
Association of Age, Frailty, and Strategy for Initiation of Renal-Replacement Therapy: A Post Hoc analysis of the STARRT-Acute Kidney Injury Trial. Blood Purif. (IF 2.2) Pub Date : 2024-07-24 Amanda Ying Wang,Ary Serpa Neto,Martin Gallagher,Ron Wald,Sean M Bagshaw,Rinaldo Bellomo,
INTRODUCTION This study was designed to assess the association of age and frailty with clinical outcomes in patients with severe acute kidney injury (AKI), according to accelerated and standard renal-replacement therapy (RRT) initiation strategies in the STARRT-AKI trial. METHODS This was a secondary analysis of an international randomized trial. Older age was defined as ≥65 years. Frailty was assessed
-
The Role of Immunomodulatory Therapy with Oxiris in COVID-19 with Renal Failure and Immune Dysfunction. Blood Purif. (IF 2.2) Pub Date : 2024-07-22 Nerea Quílez Trasobares,María González-Fernández,Jesús Abelardo Barea-Mendoza,María Dolores Arias-Verdú,Jesús Emilio Barrueco-Francioni,Gemma Seller-Pérez,Zaira Molina-Collado,Amanda Lesmes González-de Aledo,Manuel Herrera-Gutiérrez,Jose Ángel Sánchez-Izquierdo Riera
INTRODUCTION The main objective of this study was to evaluate the impact of hemoadsorption on the elimination of inflammatory mediators. METHODS A prospective, bicenter, observational cohort study was conducted between March 2020 and February 2022 to explore the immunomodulatory response, demographic and clinical characteristics of individuals with COVID-19 admitted to the ICU with severe acute respiratory
-
Comment on "Evaluating ChatGPT's Accuracy in Responding to Patient Education Questions on Acute Kidney Injury and Continuous Renal Replacement Therapy". Blood Purif. (IF 2.2) Pub Date : 2024-07-19 Hinpetch Daungsupawong,Viroj Wiwanitkit
-
A Comparison of the Anticoagulation Efficacy and Safety of Epoprostenol to Heparin and Citrate in Children Receiving Continuous Renal Replacement Therapy. Blood Purif. (IF 2.2) Pub Date : 2024-07-18 Esha Sondhi,Martha Stewart,Jenna Harper,Leslie Konyk,Coleen McSteen,Kelli L Crowley,Nahmah Kim-Campbell,Anthony Fabio,Dana Y Fuhrman
INTRODUCTION Anticoagulants are used in continuous renal replacement therapy (CRRT) to prolong filter life. There are no prior investigations directly comparing epoprostenol to more commonly used forms of anticoagulation in children. Therefore, the primary aim of this study was to assess the efficacy and safety of epoprostenol as compared to heparin and citrate anticoagulation in a pediatric cohort
-
Critically Ill Patients with COVID-19 Pneumonia Requiring Continuous Renal Replacement Therapy with oXiris® Membrane in a Third-Level Hospital in Northeast Mexico. Blood Purif. (IF 2.2) Pub Date : 2024-06-27 Paola Borbolla-Flores,Luz Yareli Villegas-Gutiérrez,Bruno Maximiliano Samaniego-Segovia,Francisco Javier Torres-Quintanilla,Juan Pablo Gómez-Villarreal,Ricardo Abraham Garza-Treviño,Lilia María Rizo-Topete
INTRODUCTION The coronavirus disease 2019 (COVID-19) pandemic represented a global public health problem with devastating consequences that have challenged conventional medical treatments. Continuous renal replacement therapy (CRRT), based on a spectrum of modalities and dialysis membranes, can modify cytokine storms, and improve the clearance of inflammatory factors. As severe COVID-19 can lead to
-
Nomogram to Estimate the Risk of Chronic Kidney Disease-Associated Pruritus in Patients with End-Stage Renal Disease Undergoing Peritoneal Dialysis: Model Development and Validation Study. Blood Purif. (IF 2.2) Pub Date : 2024-06-20 Wen Gu,Ming Zhang,Changna Liang,Shaohui Ma,Xiaopei Wang,Huijie Yuan,Zhaoyao Luo,Jing Lv
INTRODUCTION Chronic kidney disease-associated pruritus (CKD-aP) frequently occurs in patients with end-stage renal disease (ESRD) undergoing peritoneal dialysis (PD) and presents a therapeutic challenge to physicians owing to the diversity of its pathogenesis. Herein, we developed and validated a nomogram model for individualized risk estimation of CKD-aP and investigated the possible causes of CKD-aP
-
The Effects of Early-Phase, Low- or Standard-Intensity Continuous Renal Replacement Therapy on Acid-Base Control and Clinical Outcomes: An Observational Study. Blood Purif. (IF 2.2) Pub Date : 2024-06-14 Kosuke Yagi,Tomoko Fujii,Akira Kageyama,Toshishige Takagi,Junpei Ikeda,Shoichi Uezono
INTRODUCTION The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline recommends administering an effluent volume of 20-25 mL/kg/h during continuous renal replacement therapy (CRRT) for acute kidney injury. Recent evidence on CRRT initiation showed that less intervention might be beneficial for renal recovery. This study aimed to explore the association between early-phase low
-
Tachycardia and Acute Kidney Injury among Critically Ill Patients with Sepsis: A Prospective Observational Study. Blood Purif. (IF 2.2) Pub Date : 2024-06-13 Naoki Hayase,Miyuki Yamamoto,Toshifumi Asada,Rei Isshiki,Kent Doi
INTRODUCTION Tachycardia caused by sympathetic overactivity impairs myocardial function and raises septic patients' mortality. This study examined whether tachycardia is associated with acute kidney injury (AKI) period-prevalence among critically ill patients with and without sepsis. METHODS In 328 patients (119 sepsis and 209 non-sepsis) admitted to our intensive care unit (ICU), we assessed heart
-
Machine Learning-Aided Decision-Making Model for the Discontinuation of Continuous Renal Replacement Therapy. Blood Purif. (IF 2.2) Pub Date : 2024-06-12 Siyi Zhu,Jing Yan,Shijin Gong,Xue Feng,Gangmin Ning,Liang Xu
INTRODUCTION Continuous renal replacement therapy (CRRT) is a primary form of renal support for patients with acute kidney injury in an intensive care unit. Making an accurate decision of discontinuation is crucial for the prognosis of patients. Previous research has mostly focused on the univariate and multivariate analysis of factors in CRRT, without the capacity to capture the complexity of the
-
Association between Serum Magnesium Levels and Risk of Acute Kidney Injury in Patients with Traumatic Brain Injury: A Retrospective Cohort Study from the MIMIC-IV Database. Blood Purif. (IF 2.2) Pub Date : 2024-06-05 Jinbang Ma,Xiumin Li,Xinzhi Wang,Zhenxue Xin,Chuangang Wang
INTRODUCTION The occurrence of acute kidney injury (AKI) is associated with a higher risk of mortality in patients with traumatic brain injury (TBI). This study aimed to explore the relationship between serum magnesium levels and the risk of AKI in patients with TBI. METHODS Patients with TBI were identified from the Medical Information Mart Intensive Care IV (MIMIC-IV) 2008-2019. The relationship
-
Treatment with Sacubitril/Valsartan Effectively Manages Hypertension and Ameliorates Left Ventricular Hypertrophy in Hemodialysis Patients. Blood Purif. (IF 2.2) Pub Date : 2024-05-31 Nan Hu,Nan Lv,Yuqing Chen
INTRODUCTION The aim of this study was to investigate the role of sacubitril/valsartan in managing hypertension and cardiac remodeling in patients undergoing hemodialysis. METHODS Hemodialysis patients with stable blood pressure control were enrolled in the study. Sacubitril/valsartan was prescribed to replace previously used angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or other
-
Pediatric Emergent Peritoneal Dialysis in Intensive Care Units: Indications, Techniques, and Outcomes. Blood Purif. (IF 2.2) Pub Date : 2024-05-26 Yi-Hsuan Huang,Chia-Man Chou,Sheng-Yang Huang,Hou-Chuan Chen
INTRODUCTION This study aimed to identify risk factors affecting outcomes in pediatric patients requiring emergent peritoneal dialysis (PD) for all causes, focusing on survival rates, kidney function recovery, PD duration, complications, and quality of life. METHODS A retrospective review was conducted on medical records of pediatric patients who received emergent bedside PD in the intensive care unit
-
Effectiveness of Combined Hemodialysis-Hemadsorption Therapy in Improving Uremic Toxin Clearance, Inflammatory Markers, and Symptoms in Maintenance Hemodialysis Patients. Blood Purif. (IF 2.2) Pub Date : 2024-05-22 Metalia Puspitasari,Auliana Ratri Prabandari Hidayat,Wynne Wijaya,Yulia Wardhani,Prenali Dwisthi Sattwika,Jonny -,Ira Puspitawati
INTRODUCTION Combined hemodialysis (HD) and hemadsorption (HA) therapy has shown the highest clearance rates for middle and large-sized uremic toxin molecules and reduced mortality rates among maintenance HD (MHD) patients. This study aims to investigate the effectiveness of combined HD and HA therapy in patients undergoing MHD. METHODS Forty patients with end-stage renal disease (ESRD) were divided
-
Application of Nanoparticles as Novel Adsorbents in Blood Purification Strategies. Blood Purif. (IF 2.2) Pub Date : 2024-05-15 Yue Shen,Yuqi Shen,Xiao Bi,Aiwen Shen,Yifeng Wang,Feng Ding
BACKGROUND Blood purification therapy for patients overloaded with metabolic toxins or drugs still needs improvement. Blood purification therapies, such as in hemodialysis or peritoneal dialysis can profit from a combined application with nanoparticles. SUMMARY In this review, the published literature is analyzed with respect to nanomaterials that have been customized and functionalized as nano-adsorbents
-
Clarification on the Efficacy of Extracorporeal Purification Techniques in Critically Ill Patients with Liver Dysfunction. Blood Purif. (IF 2.2) Pub Date : 2024-05-08 Ivano Riva,Stefano Faenza
-
Iron Indices Mediate but Not Modify Association of Parathyroid Hormone with Erythropoietin Resistance in Hemodialysis Patients. Blood Purif. (IF 2.2) Pub Date : 2024-05-06 Xu Li,Li Zhu,Yan Wang,Yina Wang,Bei Wu,Liangying Gan,Li Zuo
INTRODUCTION Disordered iron balance and abnormal parathyroid hormone (PTH) concentrations, both prevalent in hemodialysis patients, are risk factors of erythropoietin (EPO) resistance. Few studies have evaluated the correlation between iron indices and PTH and the potential role of iron markers on the association of PTH with EPO resistance in hemodialysis population. METHODS In this cross-sectional
-
"Renal": The First Forbidden Word in the Medical Lexicon. Blood Purif. (IF 2.2) Pub Date : 2024-04-27 Rinaldo Bellomo,John A Kellum,Thiago Reis,Lui G Forni,Claudio Ronco,
-
Evaluating ChatGPT's Accuracy in Responding to Patient Education Questions on Acute Kidney Injury and Continuous Renal Replacement Therapy. Blood Purif. (IF 2.2) Pub Date : 2024-04-26 Mohammad Salman Sheikh,Charat Thongprayoon,Supawadee Suppadungsuk,Jing Miao,Fawad Qureshi,Kianoush Kashani,Wisit Cheungpasitporn
INTRODUCTION Acute kidney injury (AKI) and continuous renal replacement therapy (CRRT) are critical areas in nephrology. The effectiveness of ChatGPT in simpler, patient education-oriented questions has not been thoroughly assessed. This study evaluates the proficiency of ChatGPT 4.0 in responding to such questions, subjected to various linguistic alterations. METHODS Eighty-nine questions were sourced
-
Kinetics of Different Blood Biomarkers during Polymyxin-B Extracorporeal Hemoperfusion in Abdominal Sepsis. Blood Purif. (IF 2.2) Pub Date : 2024-04-23 Antonella Cotoia,Valeria Parisano,Paola Sara Mariotti,Vincenzo Lizzi,Giuseppe Stefano Netti,Elena Ranieri,Francesco Forfori,Gilda Cinnella
INTRODUCTION Comparison of the marker kinetics procalcitonin, presepsin, and endotoxin during extracorporeal hemoperfusion with polymyxin-B adsorbing cartridge (PMX-HA) has never been described in abdominal sepsis. We aimed to compare the trend of three biomarkers in septic post-surgical abdominal patients in intensive care unit (ICU) treated with PMX-HA and their prognostic value. METHODS Ninety abdominal
-
CCL14 Predicts Oliguria and Dialysis Requirement in Patients with Moderate to Severe Acute Kidney Injury. Blood Purif. (IF 2.2) Pub Date : 2024-04-18 Sevag Demirjian,Lakhmir Chawla,Danielle Davison,Lui G Forni,Michael Heung,Eric A J Hoste,Jay Koyner,J Patrick Kampf,Thomas Kwan,Paul McPherson,John A Kellum
INTRODUCTION AKI is a frequent complication of critical illness and portends poor outcome. CCL14 is a validated predictor of persistent severe AKI in critically ill patients. We examined the association of CCL14 with urine output within 48 h. METHODS In pooled data from 2 studies of critically ill patients with KDIGO stage 2-3 AKI, CCL14 was measured by NEPHROCLEAR™ CCL14 Test on the Astute 140® Meter
-
Nuances of Point-of-Care Ultrasound in Nephrology: A Clarion Call for Deeper Understanding. Blood Purif. (IF 2.2) Pub Date : 2024-04-17 Amir Kazory,Olanrewaju A Olaoye,Abhilash Koratala
-
Current Fluid Management Practice in Critically Ill Adults on Continuous Renal Replacement Therapy: A Binational, Observational Study. Blood Purif. (IF 2.2) Pub Date : 2024-04-16 Kyle C White,Kevin B Laupland,Marlies Ostermann,Ary Serpa Neto,Michelle L Gatton,Rod Hurford,Pierre Clement,Barnaby Sanderson,Rinaldo Bellomo
INTRODUCTION In critically ill patients undergoing continuous renal replacement therapy (CRRT), a positive fluid balance (FB) is associated with adverse outcomes. However, current FB management practices in CRRT patients are poorly understood. We aimed to study FB and its components in British and Australian CRRT patients to inform future trials. METHODS We obtained detailed electronic health record
-
In vivo Assessment of a Manual Single Lumen Alternating Micro-Batch Hemodiafiltration System. Blood Purif. (IF 2.2) Pub Date : 2024-03-27 Sabrina L Lanker,Christopher J Pino,H David Humes,Lakhmir Chawla,Kimberly A Johnston
INTRODUCTION The manual single lumen alternating micro-batch hemodiafiltration (mSLAMB) system is a closed-loop dialysis system designed to provide kidney support in emergency situations (e.g., fluid overload, hyperkalemia, acidemia). If done repeatedly in small batches and at high flow rates, this system was found to achieve clearance levels comparable to traditional renal replacement therapy. METHODS
-
Quidquid Agis, Prudenter Agas etRespice Finem!* A Tribute to Eberhard Ritz (1938-2023). Blood Purif. (IF 2.2) Pub Date : 2024-03-04 Jörg Vienken,Claudio Ronco
-
Neonatal Extracorporeal Membrane Oxygenation: Associations between Continuous Renal Replacement Therapy, Thrombocytopenia, and Outcomes. Blood Purif. (IF 2.2) Pub Date : 2024-03-01 Lauren R Walker,Laura E Hollinger,W Michael Southgate,David T Selewski,Jeffrey E Korte,Mathew Gregoski,Heidi J Steflik
INTRODUCTION The incidence of thrombocytopenia in neonates receiving extracorporeal membrane oxygenation (ECMO) with and without concurrent continuous renal replacement therapy (CRRT) and associated complications have not been well described. The primary aims of the current study were to (1) characterize thrombocytopenia in neonates receiving ECMO (including those treated concurrently with CRRT) and
-
It Is All in the Name: Standard Nomenclature for Extracorporeal Purification. Blood Purif. (IF 2.2) Pub Date : 2024-02-27 Mitchell H Rosner,Claudio Ronco
-
The Effect of Positive Pressure Ventilation on Acute Kidney Injury in COVID-19 Patients with Acute Respiratory Distress Syndrome: An Observational Study. Blood Purif. (IF 2.2) Pub Date : 2024-02-25 Lucia Zacchetti,Matteo Brivio,Mario Mezzapesa,Alessandra Martinelli,Veronica Punzi,Martina Monti,Federica Marchesi,Laura Scarpa,Rosalia Zangari,Luca Longhi,Federico Raimondi,Luca Novelli,Paolo Gritti,Lorenzo Grazioli,Gianluca Villa,Luca Ferdinando Lorini
INTRODUCTION Acute kidney injury (AKI) is frequent in critically ill COVID-19 patients and is associated with a higher mortality risk. By increasing intrathoracic pressure, positive pressure ventilation (PPV) may reduce renal perfusion pressure by reducing venous return to the heart or by increasing renal venous congestion. This study's aim was to evaluate the association between AKI and haemodynamic
-
The Use of Anemia Control Model Is Associated with Improved Hemoglobin Target Achievement, Lower Rates of Inappropriate Erythropoietin Stimulating Agents, and Severe Anemia among Dialysis Patients. Blood Purif. (IF 2.2) Pub Date : 2024-02-21 Mario Garbelli,Francesco Bellocchio,Maria Eva Baro Salvador,Milena Chermisi,Abraham Rincon Bello,Isabel Berdud Godoy,Sofia Ortego Perez,Kateryna Shkolenko,Alicia Sobrino Perez,Diana Samaniego Toro,Christian Apel,Jovana Petrovic,Stefano Stuard,Carlo Barbieri,Flavio Mari,Luca Neri
INTRODUCTION The Anemia Control Model (ACM) is a certified medical device suggesting the optimal ESA and iron dosage for patients on hemodialysis. We sought to assess the effectiveness and safety of ACM in a large cohort of hemodialysis patients. METHODS This is a retrospective study of dialysis patients treated in NephroCare centers between June 1, 2013 and December 31, 2019. We compared patients
-
Fluid Balance in Continuous Renal Replacement Therapy: Prescribing, Delivering, and Review. Blood Purif. (IF 2.2) Pub Date : 2024-02-20 Ian Charles Baldwin,Amy McKaige
BACKGROUND Historically IV and enteral fluids given during acute kidney injury (AKI) were restricted before the introduction of continuous renal replacement therapies (CRRTs) when more liberal fluids improved nutrition for the critically ill. However, fluid accumulation can occur when higher volumes each day are not considered in the fluid balance prescribing and the NET ultrafiltration (NUF) volume
-
Ultrafiltration Tolerance: A Phenotype That We Need to Recognize. Blood Purif. (IF 2.2) Pub Date : 2024-02-20 Gonzalo Ramírez-Guerrero,Claudio Ronco
BACKGROUND The evaluation and management of fluid balance are key challenges in critical care patients who require renal replacement therapies because cumulative fluid balance is an independent factor that increases morbidity and mortality in different clinical scenarios. SUMMARY One of the strategies when fluid overload is refractory to diuretics is extracorporeal fluid removal (i.e., net ultrafiltration
-
Uncomplicated Calcium-Citrate Anticoagulation during Continuous Renal Replacement Therapy in 2 Other Patients with Metformin Accumulation. Blood Purif. (IF 2.2) Pub Date : 2024-02-12 Beatrice Brunoni,Francesco Zadek,Alessandro Protti,Maurizio Cecconi,Roberto Fumagalli,Thomas Langer
-
Effect of Hemodialysis with Medium Cut-Off versus High-Flux Membranes on Endothelial Function of Patients with Chronic Kidney Disease. Blood Purif. (IF 2.2) Pub Date : 2024-02-08 Rachel Gatti Armani,Aluizio Barbosa Carvalho,Monique Vercia Rocha E Silva,Renata Verardino,Luiz Bortolotto,Maria Eugenia F Canziani
INTRODUCTION Endothelial dysfunction (ED) is considered a marker of vascular complications, especially in patients with end-stage kidney disease (ESKD). Inflammation and the uremic state contribute to ED in patients undergoing hemodialysis (HD). Recently, the medium cut-off (MCO) dialysis membrane has been proposed to efficiently remove inflammatory cytokines and large, middle-sized uremic toxins,
-
Low-Frequency/High-Frequency Ratio Is a Predictor of Death and Hospitalization in Patients on Maintenance Hemodialysis: A Prospective Study. Blood Purif. (IF 2.2) Pub Date : 2024-02-07 Yafei Chen,Xu Li,Li Zhu,Yan Wang,Liangying Gan,Li Zuo
INTRODUCTION This study aimed to evaluate the predictive value of the low-frequency/high-frequency (LF/HF) ratio in all causes of death and hospitalizations in maintenance hemodialysis (MHD) patients. METHODS This is a single-center prospective study with a 48-h electrocardiograph (ECG) recording. A total of 110 patients were enrolled in the study from October 1, 2021, to September 30, 2022. ECG recordings
-
Japanese Study of the Effects of AMG (α1-Microglobulin) Reduction Rates on Survival (JAMREDS): A Protocol of a Multicenter Prospective Observational Cohort Study. Blood Purif. (IF 2.2) Pub Date : 2024-02-04 Toshihide Naganuma,Yoshiaki Takemoto,Naohiro Kamada,Daijiro Kabata,Ayumi Shintani,Keiko Ota,Jun Minakuchi,Ken Tsuchiya,Hideki Kawanishi
INTRODUCTION Recent advances in dialysis therapy have made it possible to remove middle molecules. Removal of small-middle molecules, such as β2-microglobulin, can now be achieved with conventional hemodialysis (HD), and removal of large-middle molecules has become a target, particularly for α1-microglobulin (AMG, 33 kD). The AMG reduction rate has emerged as a target for improvement of various clinical
-
The Changes in Relative Blood Volume during Dialysis Are Characterized by Ultrafiltration Rate and Predialysis Blood Test Values. Blood Purif. (IF 2.2) Pub Date : 2024-02-04 Tomoyuki Tanaka,Yoshifumi Kawakubo,Takeshi Shigematsu,Haruhiko Nishimura
INTRODUCTION Continuous monitoring of relative blood volume (percentage BV) in hemodialysis (HD) is critical for determining dry weight and preventing intradialytic hypotension. However, the cause of the BV variation remains unknown. This research aimed to examine factors that influence the percentage BV. METHODS We devised a formula based on coefficients ("a," "τ," and "b") to predict changes in percentage
-
Global Scientific Trends in Continuous Renal Replacement Therapy from 2000 to 2023: A Bibliometric and Visual Analysis. Blood Purif. (IF 2.2) Pub Date : 2024-02-04 ZhongBin Tao,YanDong Feng,Jie Wang,YongKang Zhou,JunQiang Yang
INTRODUCTION Continuous renal replacement therapy (CRRT) is one of the most widely used blood purification and organ support methods in the ICU. However, the development process, the current status, hotspots, and future trends of CRRT remain unclear. METHOD The WoSCC database was used to analyze CRRT research evolution and theme trends. VOSviewer was used to construct coauthorship, co-occurrence, co-citation
-
Effect of Mechanical Vibration on Kinetics of Solute Adsorption. Blood Purif. (IF 2.2) Pub Date : 2024-01-27 Gonzalo Ramírez-Guerrero,Thiago Reis,Anna Lorenzin,Matteo Marcello,Massimo de Cal,Monica Zanella,Claudio Ronco
INTRODUCTION Hemadsorption with new sorbent cartridges is an emerging extracorporeal blood purification technique. Flow distribution inside the sorbent is one of the main issues concerning the device's performance and optimal sorbent utilization. In this experiment, we aimed to investigate the efficacy of vibration during adsorption by measuring the removal of vancomycin. METHODS In this experimental
-
In vitro Removal of Protein-Bound Retention Solutes by Extracorporeal Blood Purification Procedures. Blood Purif. (IF 2.2) Pub Date : 2024-01-23 Claudia Schildboeck,Stephan Harm,Jens Hartmann
INTRODUCTION When the kidneys or liver fail, toxic metabolites accumulate in the patient's blood, causing cardiovascular and neurotoxic complications and increased mortality. Conventional membrane-based extracorporeal blood purification procedures cannot remove these toxins efficiently. The aim of this in vitro study was to determine whether commercial hemoperfusion adsorbers are suitable for removing
-
Angiopoietin as a Novel Prognostic Marker in Kidney Disease. Blood Purif. (IF 2.2) Pub Date : 2024-01-23 Abdullah B Yildiz,Sidar Copur,Cem Tanriover,Furkan Yavuz,Sezan Vehbi,Abduzhappar Gaipov,Lorenza Magagnoli,Paola Ciceri,Mario Cozzolino,Mehmet Kanbay
INTRODUCTION Renal injury is among the leading causes of morbidity and mortality; however, there are no reliable indicators for determining the likelihood of developing chronic kidney disease (CKD), CKD progression, or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization, and inflammation and have been implicated as
-
Protein Kinase N1 Level Predicts Acute Kidney Injury in Patients Undergoing Cardiac Surgery: A Prospective Cohort Study. Blood Purif. (IF 2.2) Pub Date : 2024-01-16 Lianjiu Su,Fangfang Zhu,Jiahao Zhang,Edward Z Cao,Cheng Yang,Haibing Sun,Xiaofang Jiang,Xiaozhan Wang,Jing Wang,Zhiyong Peng
INTRODUCTION The objective of this study was to examine the utility of protein kinase N1 (PKN1) as a biomarker of cardiac surgery-associated AKI (CSA-AKI). METHODS A prospective cohort study of 110 adults undergoing on-pump cardiac surgery was conducted. The associations between post-operative PKN1 and CSA-AKI, AKI severity, need for renal replacement therapy (RRT), duration of AKI, length of ICU stay
-
Effects of Extracorporeal Blood Flow Rates on Patient Tolerance for LIXELLE® Treatment during Outpatient Hemodialysis. Blood Purif. (IF 2.2) Pub Date : 2024-01-16 Onkar S Dhande,Arnaud Teichert,Varshasb Broumand,Haruki Kakita,Ayaka Kitamura,Masaaki Fukunishi,Christos P Argyropoulos,Eva Czirr,Peter J Nelson
INTRODUCTION Accumulation of β2-microglobulin (B2M) in dialysis patients contributes to several comorbidities of end-stage kidney disease (ESKD). The LIXELLE® device adsorbs B2M from blood using sorbent bead technology. Studies in Japan showed that LIXELLE treatment during hemodialysis (HD) at blood flow rates up to 250 mL/min removes B2M above HD alone and is well tolerated. We investigated tolerance
-
Application of Lipid Apheresis in Acute Lipogenic Pancreatitis. Blood Purif. (IF 2.2) Pub Date : 2024-01-16 Yan Yu,Fang Yuan,Pan'ai Song,Cuifang Sun,Hao Xiong,Jie Song
INTRODUCTION Recently, the incidence of hypertriglyceridemia-associated pancreatitis (HTG-AP) has been increasing. The pathogenesis of lipogenic pancreatitis is not fully understood. This study aimed to retrospectively analyze the laboratory data, clinical manifestations, and prognosis of patients with lipid-derived pancreatitis who received lipid purification, to explore whether lipid purification